U.S. Markets closed

Biotest Aktiengesellschaft (BIO3.DE)

XETRA - XETRA Precio retrasado. Divisa en EUR.
Añadir a la lista de seguimiento
26.90-0.20 (-0.74%)
Al cierre: 5:36p.m. CEST

Biotest Aktiengesellschaft

Landsteinerstrasse 5
Dreieich 63303
Germany
49 6103 801 0
http://www.biotest.com

Sector(es)Healthcare
IndustriaBiotechnology
Empleados a tiempo completo1,871

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Dr. Michael RamrothChairman of the Management Board, CEO & CFO1.11MN/D1961
Dr. Georg FloßCOO & Member of the Board of Management882kN/DN/D
Dr. Monika ButtkereitHead of Investor RelationsN/DN/DN/D
Dr. Christina ErbHead of Corp. HRN/DN/DN/D
Dr. Katrin BernösterHead of the Project Management OrganisationN/DN/DN/D
Mr. Peter SeithHead of Quality OperationsN/DN/DN/D
Dr. Jörg SchüttrumpfHead of R&DN/DN/DN/D
Dr. Wolfgang MöllerHead of Devel. - Plasma ProteinN/DN/DN/D
Dr. Hermann KeuperSr. VP of ManufacturingN/DN/DN/D
Los importes son a partir de 31 de diciembre de 2019 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en EUR.

Descripción

Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in haematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in newborns; Hepatect for prophylaxis of hepatitis B re-infection; Intratect for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; IgG Next Genration for primary immune deficiency and immunothrombocytopenia; Varitect for the treatment of varicella zoster virus infections; Zutectra for hepatitis B re-infection prophylaxis after liver transplantation; and Cytotect 70(BT-094) for prevention of cytomegalovirus infection in the foetus during pregnancy with mother's CMV infection. In addition, it provides Albiomin for the treatment of blood volume depletion; Biseko to treat volume and serum protein depletion; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital and acquired fibrinogen deficiency; Trimodulin for the community-acquired pneumonia; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany. Biotest Aktiengesellschaft is a subsidiary of Tiancheng International Investment Limited.

Gestión corporativa

La calificación ISS Governance QuickScore de Biotest Aktiengesellschaft a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.